Dr Reddy's gets USFDA nod for migraine injection

Dr Reddy
Highlights

Pharma major Dr Reddy\'s Laboratories on Friday said it has received USFDA approval to market ZembraceSymTouch injection, a drug-device combination product intended for the treatment of acute migraine, in the US market.

Hyderabad: Pharma major Dr Reddy's Laboratories on Friday said it has received USFDA approval to market ZembraceSymTouch injection, a drug-device combination product intended for the treatment of acute migraine, in the US market.

The company has received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection, Dr Reddy's said.
ZembraceSym Touch is available as a prefilled, ready to use, single dose disposable autoinjector, containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.

"This is a major milestone for the company as we continue to bring innovative medicines to patients and physicians," GV Prasad, CEO and Co-Chairman, Dr Reddy’s Laboratories. The new product will be marketed in the US by Promius Pharma, a wholly-owned subsidiary of the company.

"ZembraceSymTouch is the first branded product in the company's neurology portfolio," said Raghav Chari, Executive Vice President (Propriety Products Group), Dr Reddy’s.

Migraine affects millions of patients, many of these patients have busy lives and quick pain relief is critical to help them manage their daily routines. In many cases migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills, he added.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
More Stories


Top